Global Enzyme Replacement Therapy Market Report 2023: Forecast Market Size, Growth Rate And Key Drivers
26 Jul, 2023
The global enzyme replacement therapy market size is expected to grow from $10.03 billion in 2022 to $10.85 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions and affecting many markets across the globe. The global enzyme replacement therapy market size is expected to reach $14.79 billion in 2027 at a CAGR of 8.1%.
Global Enzyme Replacement Therapy Market Key Driver
The increased prevalence of rare, chronic, and inherited illnesses is likely to move the enzyme replacement treatment industry forward in the coming years. Chronic disease is a type of illness that lasts three months or longer and can worsen over time. Chronic diseases are more common in the elderly and can usually be treated but not removed.
Get a sample of the global enzyme replacement therapy market reportGlobal Enzyme Replacement Therapy Market Segments
The global enzyme replacement therapy market is segmented:
1) By Enzyme Type: Agalsidase Alfa, Agalsidase Beta, Galsulfase, Other Enzyme Types
2) By Application: Gaucher Disease, Pompe Disease, Fabry Disease, Other Applications
3) By Route Of Administration: Oral, Parenteral
4) By End-Users: Hospitals, Infusion Centers, Other End-Users
5) By Geography: The regions covered in the enzyme replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions, North America accounts for the largest share in the global enzyme replacement therapy market.
Major Enzyme Replacement Therapy Industry Players
Biomarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Protalix BioTherapeutics Inc., Amicus Therapeutics Inc., Johnson & Johnson Services Inc., Digestive Care Inc., Nestle Health Science, Alexion Pharmaceuticals Inc., Allergan Plc., Actelion Pharmaceuticals Ltd., CANbridge Life Sciences Ltd., Chiesi Farmaceutici S.P.A., Astrazeneca Plc., Genzyme Corporation, JCR Pharmaceutical Co. Ltd., TEIJIN LIMITED, Horizon Therapeutics Plc., Perseo Pharma AG, SmartPharm Therapeutics Inc.
Get the full global enzyme replacement therapy market report
Enzyme Replacement Therapy Market Overview
Enzyme replacement therapy (ERT) refers to a sort of medical treatment in which patients with chronic disorders brought on by insufficient or failing enzymes are given alternative enzymes. The body can complete the processes inhibited by the deficit by getting enzyme replacements. It is particularly effective at returning urinary GAG levels to normal and boosting liver and spleen development.
Enzyme Replacement Therapy Global Market Report 2023 provides data on the global enzyme replacement therapy market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The enzyme replacement therapy market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.